XOLREMDI® (mavorixafor)
WHIM syndrome (patients 12 years and older)
ApprovedCommercial; launched in U.S. May 2024. MAA under review in EU.
Key Facts
Indication
WHIM syndrome (patients 12 years and older)
Phase
Approved
Status
Commercial; launched in U.S. May 2024. MAA under review in EU.
Company
About X4 Pharmaceuticals
X4 Pharmaceuticals is a publicly traded biotech focused on rare immune disorders, leveraging its expertise in the CXCR4 pathway. The company achieved a major milestone with the 2024 FDA approval and U.S. launch of XOLREMDI® for WHIM syndrome, its first commercial product. X4 is now advancing mavorixafor into a pivotal Phase 3 trial for chronic neutropenia and has established commercialization partnerships in Europe and the Middle East, positioning itself as a commercial-stage rare disease company.
View full company profile